Friday April 26, 2019 23:23

Heathcare Press Release : 20 Mar 2019

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Heathcare—20 Mar 19

Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in

UK Schools Rank Last in Providing Oral Health Education, FDI Survey of 13 Countries Heathcare—20 Mar 19

Today on World Oral Health Day (WOHD), FDI World Dental Federation (FDI) released the results of a survey from 13 countries, which asked parents with children aged 5–16 if their child's school provided lessons on good oral care. Poor oral health